Peptides: The Science, Uses & Safety | Dr. Abud Bakri

People are stacking GLP‑1s with hormone and growth‑hormone modulation as a fast‑track body makeover. Whether that’s wise is still unclear, but it’s the celebrity playbook right now—welcome to the show.

Welcome to the Huberman Lab podcast, where we dig into science and practical tools. Today I’m joined by Dr. Abboud Bakery, an internal‑medicine physician with deep expertise in peptides, from FDA‑approved GLP agonists to compounds like BPC‑157, growth‑hormone secretagogues, GHK‑copper, and longevity candidates such as epitalon and pinealon; we’ll separate what’s known from what’s unknown and focus hard on safety.

Before we talk use cases, help us frame peptides. How should people think about this huge category?

I view peptides as one of the body’s signaling languages. Clinically, I split them into those with defined receptors—like the GLP‑1s—and those without a clear single target, such as BPC‑157 or TB‑500, which likely act through broader protein or epigenetic effects.

So two big buckets: receptor‑mapped peptides versus ones with less defined binding but intriguing biology. Let’s start with BPC‑157—what is it, and why the buzz?

A Croatian team in the 1990s purified a large ‘body protection compound’ from gastric tissue and narrowed a 15‑amino‑acid fragment now called BPC‑157. Humans don’t make that exact fragment, but the idea sprang from older observations—think Pavlov’s gastric extracts and Hans Selye’s stress‑ulcer findings—that the gut likely holds cytoprotective factors.

What did the animal work actually show that got everyone’s attention?

In rodent models, BPC‑157 accelerated healing of tendons and ligaments, improved burn and ulcer outcomes, and reduced stress‑related gut damage; musculoskeletal hype followed, even though the earliest aim was gastric protection.

Mechanistically, how could one peptide touch tendon, nerve, and gut?

It appears to amplify repair programs: more angiogenesis signals like VEGF, better cell migration, nitric‑oxide modulation, and even more growth‑hormone receptors in injured tendon; neurologically, it tempered alcohol intoxication and withdrawal in rodents, and anecdotally seems to blunt stimulant effects—hinting at gut–brain dopamine and GABA pathways.

Any documented adverse events unrelated to contamination, and what do we know about dosing safety?

Animal studies pushed doses hundreds to thousands of times higher without finding an LD50. Small Croatian phase 1–2 trials using high‑dose rectal administration for ulcerative colitis reported no safety signals, though only abstracts exist and pharmacokinetics suggest minimal systemic detection with that route.

Some people discount data outside the U.S.; is that fair here?

I’d judge the methods, not the map. Skepticism of Soviet‑era exaggeration is warranted, but being U.S.‑centric can blind us; still, most BPC literature traces to one group, so independent replication is crucial.

What’s the current U.S. status—can a clinician prescribe it, and what’s with ‘pentadecapeptide’ labels?

BPC‑157 isn’t FDA‑approved. It was moved to a ‘do not compound’ list in late 2024, then removed from that in April, but not yet green‑lit; some pharmacies sell it as ‘pentadecapeptide’ with a different salt form. State boards vary, and telehealth follows the patient’s location, so it’s a patchwork.

There was a rumor of an Olympic Achilles rupture fixed by BPC injections. Any proof?

No verification, and elite rehabs rarely rely on a single tool. The broader surge came from GLP‑1 shortages pushing compounding and gray‑market activity, plus providers marking up compounds—patients should absolutely ask what the clinic pays versus what they’re charged.

Quality control is the elephant in the room. How do compounded and gray‑market peptides compare?

All roads start with Chinese API, then quality diverges—some compounders are excellent, others not; gray‑market vials range from clean to mislabelled, even wrong drugs. Batch variability is the biggest risk.

This isn’t just a bodybuilding niche. Women’s interest in GHK‑copper and collagen repair seems huge.

It already skews female by volume, and affiliate sales have exploded, which further blurs medical oversight.

My main concern is angiogenesis. If someone has an occult tumor, could BPC speed its growth?

So far, animal data don’t show carcinogenic signals, though most studies trace to one lab. We do see reports of more visible angiomas or hematomas, which fit its pro‑vascular effects, yet in some models it down‑regulates VEGF—so it may be context‑dependent; proper human trials are starting, including a U.S. tendon study, and we’re working to aggregate real‑world outcomes.

Given the Wild‑West feel, what can you responsibly do for a patient who might benefit?

In the hospital, recommending a non‑approved injectable could cost a license; in clinic, with clear consent and if regulations allow, a cautious, monitored trial might be reasonable. Orals sit in a gray zone where they’re sold as supplements, but bioavailability and purity are uncertain.

If we could fund rigorous studies, what endpoints deserve priority?

I’d run a phase‑3 trial in ulcerative colitis, a GERD study versus a proton‑pump inhibitor, a controlled addiction‑craving trial through the gut–brain axis, and a post‑op tendon protocol to test faster, higher‑quality healing.

Anecdotally, I’ve seen rapid relief of a neck‑trap strain after a tiny local injection, but we can’t ascribe causality. Not everyone benefits, and source and dose matter.

I tore my triceps and used high local doses with other agents; my recovery was shockingly fast for that grade of injury, though we still lack validated human dosing. Either this compound is a missed medical opportunity or a risky fad—only real data will tell.

Let’s pivot to pinealon. I’ve tested tiny doses before second‑half sleep and reliably get far more REM, with a lingering uplift in REM on off nights. What is pinealon, and how does it work?

Pinealon is a brain‑derived tripeptide identified by Vladimir Kavinson’s group, born from Soviet efforts to protect circadian rhythm and immunity in submariners and cosmonauts; it lacks a classic receptor and likely acts via epigenetic routes. Importantly, epitalon comes from the pineal gland and boosts melatonin output in aged animals and humans, whereas pinealon was isolated from a cortical extract—names are confusing, but the origins differ.

Let’s rename pinealon to EDR so no one confuses it with the pineal, and here’s my puzzle: I’m seeing more REM when I take it. I can’t placebo myself during sleep, so why would a tiny tripeptide with no classic receptor bump REM?

The old Cavinson papers never tracked REM, but EDR appears to slip into DNA grooves and help transcription factors do their job, which seems to lift brain metabolism. It nudges pathways like GDF11, SOD1 and SOD2, irisin, and PPAR alpha and gamma; folks report crisper thinking, less fog, and even steadier performance under fatigue, which is why I suggest morning dosing for cognition and training. Orally, people land between half a milligram and three milligrams, some inject, and it likely crosses into the brain; side notes include vivid, color‑rich dreams, a small blood sugar drop, and in some, lower A1C.

I’m very sensitive. Half the suggested dose gives me great sleep, while the full dose sends me into deep sleep with wild dreams and questionable architecture. I only touch it a few times a month.

Switching gears to epitalon from the pineal: I used to dismiss talk of pineal calcification, then the literature made me reconsider. Even if it does calcify, does that actually blunt function, and can epitalon help?

Pineal research is oddly neglected, but Cavinson’s group showed epitalon can restore rhythmicity in peripheral clock genes and raise morning cortisol, which better anchors circadian hormones. His model is pulse, then coast—take short courses and keep accruing benefit. In a long nursing home study, yearly short cycles of pineal plus thymic peptides were linked to lower deaths from heart disease, infections, and cancer—promising, though it is Russian data.

I got keen on epitalon because of retinal neuroprotection data in mice. It felt less like a vague receptor story and more like DNA repair support. Do you see it as a mini gene therapy, or a tune‑up for core machinery?

More a tune‑up. I suspect it also boosts melanopsin in the retina, which could make morning light cues more potent—darkness upregulates melanopsin in animal studies, so epitalon might amplify that system.

A quick cautionary tale: medicine has gotten big calls wrong, like thymus irradiation in kids a century ago. With peptides, we should stay excited and careful.

Walk us through the thymus. How fast does it fade, how is it controlled, and can we bring it back?

The thymus is huge in childhood, sits over the heart, and trains T cells to attack threats without attacking you. It shrinks after puberty under the push of sex steroids and corticosteroids, but can wax and wane with states like pregnancy and even hibernation; removing residual thymus tissue correlates with higher cancer and autoimmunity risk. In the TRIIM trial, a cocktail of growth hormone, metformin, and DHEA enlarged thymic tissue and improved T cell markers, hinting we can revive output.

People always ask about thymosin alpha‑1. What does it naturally do?

It is an immune accelerator that promotes T cell maturation and appropriate targeting. It had an FDA‑approved life as Zadaxin for specific immunodeficiencies and is used abroad as an adjuvant in hepatitis and oncology; sepsis data are mixed. I use small twice‑weekly doses during travel to avoid getting sidelined, but that is not an FDA‑approved prophylactic use.

And TB‑500—how is it different, and do these tie back to athletics and even animals?

TB‑500 is thymosin beta‑4, which regulates the actin cytoskeleton so immune and repair cells move and remodel tissue. It is popular in animal sports because of that mobility and healing angle. On pets, I’m broadly supportive because much of the data started in animals and many vets are pragmatic, but quality matters and regulation is unsettled, like whether oral BPC is a supplement or a drug. Also, skip animal‑organ extracts—prions are a real risk, and they largely halted that research wave. Modern thymic work distinguishes mixes from single peptides: thymulin is a nine‑amino‑acid, zinc‑dependent signal that not only supports NK and T cells but also sensitizes endocrine targets; for instance, it can potentiate LH or HCG effects on testosterone in animals. Practically, good zinc status helps you make thymulin yourself.

GHK‑copper keeps coming up, especially from women asking about skin. Should it be used topically, systemically, or both?

GHK‑Cu is a tripeptide embedded in type one collagen that falls with age and appears to coordinate collagen build‑and‑break for proper remodeling. Topically, well‑formulated products have human data for improving photoaging; hair results are modest, while injections speed wound closure in animals and are being explored for lung repair. If you go topical, use a reputable formulation that can deliver it through skin; the blue tint alone does not prove quality. Many pair it with red light, which seems synergistic for collagen support.

On GLP‑1s, people report less appetite but also less drive. Some microdose, some share pens, and sourcing can be sketchy. How do you view these in the larger health landscape?

They are reshaping metabolic care. Semaglutide and tirzepatide take off significant weight—often ten to thirty percent—lowering risks tied to obesity and diabetes. The set‑point model explains why stopping can bring weight back, so I treat them like training wheels: lowest effective dose, steady titration, and build habits so you can maintain gains. Blunted motivation may reflect dosing too high, poor hydration, low electrolytes, micronutrient gaps, or less social eating; when used thoughtfully, I hear far fewer mood complaints. These drugs also dampen alcohol drive and interact with dopamine circuits, which matters when people stack them with stimulants.

Some friends report clearer thinking, but that could be from less fat and better insulin sensitivity. Leptin keeps popping up here—what shifts do you see?

As fat mass drops, leptin sensitivity improves, which can restore fertility; many so‑called Ozempic babies are likely from weight‑driven normalization of reproductive signals. Leptin thresholds also help trigger puberty timing, so it tracks that energy status gates reproduction.

Have you tried a GLP‑1 yourself?

Once, to test a suspect pen. I jumped to one milligram and paid for it with relentless nausea while on call—do not do that. It drove home why slow titration and clean sourcing matter. Looking ahead, retatrutide will likely expand indications, and manufacturers may push to classify it as a biologic to extend protection and limit compounding. The bigger issue is that “peptides” is too broad a bucket; we need clear, receptor‑based categories so people know what they are actually taking.

I’d love you to spearhead that nomenclature effort. Two quick audience questions before we pause. First, for endometriosis or fibroids, does BPC help or hurt?

There is no solid animal or human evidence tying BPC to better or worse outcomes there. Those conditions are far more hormone‑driven than peptide‑driven, so I would not lean on BPC for them.

Last one for now: any central nervous system effects of BPC or related peptides—good or bad—and could they help after brain injury?

Some TBI work from Russia looked at compounds unlikely to be offered here, so I set that aside. For BPC, animal data point to a steadying effect on the nervous system that blunts big swings, which could explain reports of flat mood; it may push the body toward a rest‑and‑repair mode, but we need solid studies to know.

If someone wants to try peptides, not the GLPs, how do they do it safely? Where should they go, whom should they trust, and how can they know what they are getting is clean and accurate?

Right now most people buy from research-only sites, and quality there is a black box. The better path is clinician-guided care through compounding pharmacies, and telemedicine options are about to expand, which should improve access and drive costs down while making quality easier to compare. Build a relationship with a physician who understands peptides, and physicians should get up to speed because this era is here. Expect an influx of oral peptides on supplement shelves, but we need clearer rules from regulators on what can be sold. Use peptides under medical supervision and track relevant labs, for example monitoring IGF‑1 with growth hormone secretagogues. Do not skip fundamentals like morning light, real sleep in darkness, and minimally processed food; protocols that layer lifestyle with peptides will make the most sense. Within about six months there should be strong physician-led options for most people.

Thank you for unpacking the science, the limits, and the real risks with such clarity. I want to bring you back to dig into hormones in men and women, pregnancy physiology, and how things like progesterone can shape male development, but for now we’ll let people absorb this and we’ll link to your work in the show notes, including your new circadian biology app. If you are learning from this show, please subscribe on YouTube, follow on Spotify and Apple, leave a five‑star review if you think we have earned it, and drop your questions in the YouTube comments because I do read them. My first book, Protocols, an operating manual for the human body, is now available for pre‑order at protocolsbook.com and covers sleep, exercise, stress tools, focus, and motivation with the underlying science. You can find me as Huberman Lab on Instagram, X, Threads, Facebook, and LinkedIn for related science and tools. You can also join our zero‑cost Neural Network newsletter at HubermanLab.com for concise summaries and protocol PDFs on topics like sleep, dopamine, and deliberate cold exposure; we do not share your email. Thanks again for being here, and thanks for your interest.

It was a pleasure to be here, and I appreciate the kind words.